The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk

John B. Anderson, Claus Roehrborn, Jack A. Schalken, Mark Emberton

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others. Objective: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed. Conclusion: Strategies to identify patients most at risk and guidelines directed towards long-term management, in addition to short-term treatment, may be useful in helping to prevent BPH progression.

Original languageEnglish (US)
Pages (from-to)390-399
Number of pages10
JournalEuropean Urology
Volume39
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Prostatic Hyperplasia
Lower Urinary Tract Symptoms
Urinary Retention
Practice Management
Prostate
Quality of Life
Guidelines

Keywords

  • 5α-Reductase inhibitors
  • Benign prostatic hyperplasia
  • Dihydrotestosterone
  • Progression

ASJC Scopus subject areas

  • Urology

Cite this

The progression of benign prostatic hyperplasia : Examining the evidence and determining the risk. / Anderson, John B.; Roehrborn, Claus; Schalken, Jack A.; Emberton, Mark.

In: European Urology, Vol. 39, No. 4, 2001, p. 390-399.

Research output: Contribution to journalArticle

Anderson, John B. ; Roehrborn, Claus ; Schalken, Jack A. ; Emberton, Mark. / The progression of benign prostatic hyperplasia : Examining the evidence and determining the risk. In: European Urology. 2001 ; Vol. 39, No. 4. pp. 390-399.
@article{58b585cd3a0641388a35acdff4b8e691,
title = "The progression of benign prostatic hyperplasia: Examining the evidence and determining the risk",
abstract = "Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others. Objective: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed. Conclusion: Strategies to identify patients most at risk and guidelines directed towards long-term management, in addition to short-term treatment, may be useful in helping to prevent BPH progression.",
keywords = "5α-Reductase inhibitors, Benign prostatic hyperplasia, Dihydrotestosterone, Progression",
author = "Anderson, {John B.} and Claus Roehrborn and Schalken, {Jack A.} and Mark Emberton",
year = "2001",
doi = "10.1159/000052475",
language = "English (US)",
volume = "39",
pages = "390--399",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - The progression of benign prostatic hyperplasia

T2 - Examining the evidence and determining the risk

AU - Anderson, John B.

AU - Roehrborn, Claus

AU - Schalken, Jack A.

AU - Emberton, Mark

PY - 2001

Y1 - 2001

N2 - Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others. Objective: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed. Conclusion: Strategies to identify patients most at risk and guidelines directed towards long-term management, in addition to short-term treatment, may be useful in helping to prevent BPH progression.

AB - Background: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute urinary retention, may ensue. Evidence is emerging from long-term clinical studies to suggest that BPH is a progressive disease, with some patients progressing much more rapidly than others. Objective: This article aims to explore the natural history of BPH progression from a molecular, pathological and clinical perspective, with emphasis on the key clinical evidence to support the progressive nature of this disease. How our increased understanding of the disease and of the risk factors for BPH progression might be applied to improve current management practices are also discussed. Conclusion: Strategies to identify patients most at risk and guidelines directed towards long-term management, in addition to short-term treatment, may be useful in helping to prevent BPH progression.

KW - 5α-Reductase inhibitors

KW - Benign prostatic hyperplasia

KW - Dihydrotestosterone

KW - Progression

UR - http://www.scopus.com/inward/record.url?scp=0035049190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035049190&partnerID=8YFLogxK

U2 - 10.1159/000052475

DO - 10.1159/000052475

M3 - Article

C2 - 11306876

AN - SCOPUS:0035049190

VL - 39

SP - 390

EP - 399

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -